Skip to main content

Table 3 Baseline characteristics of the patients in the sharp and phase I/II trial

From: Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma

Characteristics SHARP trial Phase I/II trial P value
Age, years 64.9 69.4 0.22
Male no (%) 260 (87 %) 80 (78.4 %) 0.244
Underlying liver disease    0.011
 Hepatitis B 56 (19 %) 39 (38.2 %)  
 Hepatitis C 87 (29) 39 (38.2 %)  
 Alcohol related 79 (26 %) 25 (24.5 %)  
 Other 28 (9 %) 14 (13.7 %)  
 Unkown 49 (16 %) 7 (6.9)  
ECOG performance status n (%)    0.225
 0 161 (54 %) 85 (83.3)  
 1 114 (38 %)  
 2 24 (8 %) 11 (10.8 %)  
BCLC stage    0.208
 B (intermediate) 54 (18 %) 35 (34.3 %)  
 C (advanced) 244 (82 %) 67 (65.7 %)  
Child-Pugh class, no (%)    < 0.0001
 A 284 (95 %) 102 (100 %)  
 B 14 (5 %) 0 %  
Biochemical analysis    0.25
 Albumin (g/dl) 3.9 4.0  
 Total bilirubin (mg/dl) 0.7 1.3  
 Alpha-fetoprotein 44.3 ng/ml 163 nmol/L  
Previous therapy    0.079
 Surgery 57 (19 %) 9 (8.8 %)  
 TACE 86 (29 %) 22 (21.6 %)  
 RFA 17 (6 %) 35 (34.3 %)  
 PEI 28 (9 %) 16 (15.7 %)  
Extrahepatic spread (no,%) 159 (53 %) 12 (11.8 %) < 0.0001
Vascular invasion (no,%) 108 (36 %) 20 (49 %) < 0.0001
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group, BCLC Barcelona Clinic Liver Cancer staging system, TACE transarterial chemoembolization, RFA radiofrequency ablation, PEI percutaneous ethanol injection